Protalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/30/21
Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business ResultsPRNewsWire • 03/30/21
Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021PRNewsWire • 03/22/21
Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences ConferencePRNewsWire • 03/04/21
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross ProceedsPRNewsWire • 02/18/21
Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common StockPRNewsWire • 02/12/21
Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory ConditionsBenzinga • 02/11/21
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled DeliveryPRNewsWire • 02/11/21
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021PRNewsWire • 02/10/21
Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021PRNewsWire • 02/01/21
Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in JanuaryPRNewsWire • 01/04/21
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry DiseasePRNewsWire • 12/30/20
FDA Decision For Protalix Postponed Due To Covid, But Fundamentals Remain StrongSeeking Alpha • 12/28/20
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry DiseasePRNewsWire • 11/27/20
Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel ConferencePRNewsWire • 11/05/20
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/01/20
Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30PRNewsWire • 10/29/20
Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdatePRNewsWire • 10/29/20
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry DiseasePRNewsWire • 10/02/20